In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Timing the Stem Cell Opportunity

Executive Summary

Companies are drawing parallels between the monoclonal antibody industry and stem cells, and they are trying to strike a balance between gaining a stake in a field with tremendous potential without being too early. Stem cells have the potential to treat some of the largest degenerative diseases in the cardiovascular, neurological, orthopedic segments--markets worth in the double digit billions, according to a recent report on Tissue Engineering, issued by Medtech Insight. No company wants to be left behind.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts